GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$77.95
-0.30 (-0.38%)
▼
5d:
-5.56%
30d:
-13.96%
90d:
-13.83%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$134.87
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$83.74
6.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $77.95, which is considered slightly low relative to its 30-day fair value range of $77.84 to $88.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.1) compared to its historical average (19.3). Remarkably, the market is currently pricing in an annual earnings decline of 7.8% over the next few years. This pessimistic expectation contrasts with the company's recent 66.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a downtrend. The price is currently testing key support at $77.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMED has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $110.00 (+41.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GMED is in a downtrend. The price is currently testing key support at $77.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMED has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $110.00 (+41.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$77.84 -
$88.76
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.1% below Wall St target ($110.00)
- CAUTION: 5-day price weakness (-5.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$77.84 -
$88.76
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$77.41
Resistance Level
$86.02
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.13
Wall Street Target
$110.00
(+41.1%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
66.7%
Profit Margin
18.9%
Valuation Discount vs History
-7.8% cheaper
PE vs Historical
15.1 vs 19.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.8%
(market-implied from PE analysis)
1-Year Target
$71.87
(-8%)
2-Year Target
$66.26
(-15%)
3-Year Target
$61.10
(-22%)
3-Yr Target (if PE normalizes)
(PE: 15→19)
$77.93
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 8.6%)
$144.53
(+85%)
Base:
(SPY PE: 15.1, Growth: 8.6%)
$99.82
(+28%)
Bear:
(PE: 12.9, Growth: 8.6%)
$84.85
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 19.29 | Current EPS (TTM): $4.28
Bull Case
$109.09
(+32%)
Analyst growth 20.2%, PE expands to 21.2
Base Case
$99.18
(+20%)
Market implied 20.2%, PE stable at 19.3
Bear Case
$56.13
(-32%)
Severe decline -20.0%, PE contracts to 16.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.1 to 19.3
Stabilization Target:
$99.42
(+27.5%)
PE Expansion Potential:
+27.5%
Share & Embed Analysis
Last updated: June 04, 2026 1:32 AM ET
Data refreshes hourly during market hours. Next update: 2:32 AM
Data refreshes hourly during market hours. Next update: 2:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Kelly Huller
SELL
20000 shares
2026-02-25
Kelly Huller
SELL
10000 shares
2026-02-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$83 | 54 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$82 | 64 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 64 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$107 | 61 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
